Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Romain Corre

Showing results (21-30 of 54) with videos related to

Pageof 6
Sort By:
Oncotarget|March 2, 2018
Octogenarians with EGFR-mutated non-small cell lung cancer treated by tyrosine-kinase inhibitor: a multicentric real-world study assessing tolerance and efficacy (OCTOMUT study)Romain Corre, Radj Gervais, Florian Guisier, et al.
Oncology|October 3, 2018
Characteristics of Lung Cancer in Patients Younger than 40 Years: A Prospective Multicenter Analysis in FranceLaurence Bigay-Gamé, Suzanna Bota, Laurent Greillier, et al.
Infectious Diseases Now|July 9, 2021
Hypermetabolic pulmonary lesions on FDG-PET/CT: Tularemia or neoplasia?Pauline Martinet, Lydie Khatchatourian, Nadia Saidani, et al.
Lung Cancer (Amsterdam, Netherlands)|January 9, 2020
Immunotherapy rechallenge after nivolumab treatment in advanced non-small cell lung cancer in the real-world setting: A national data base analysisMatteo Giaj Levra, François-Emery Cotté, Romain Corre, et al.
Translational Lung Cancer Research|March 10, 2023
Pembrolizumab plus pemetrexed-carboplatin combination in first-line treatment of advanced non-squamous non-small cell lung cancer: a multicenter real-life study (CAP29)Emmanuelle Renaud, Charles Ricordel, Romain Corre, et al.
Cancer Medicine|August 24, 2022
Real-life second-line epirubicin-paclitaxel regimen as treatment of relapsed small-cell lung cancer: EpiTax studyJosselin Annic, Hélène Babey, Romain Corre, et al.
Targeted Oncology|May 24, 2019
Real-Life Efficacy of Osimertinib in Pretreated Octogenarian Patients with T790M-Mutated Advanced Non-small Cell Lung CancerJean-Bernard Auliac, Karima Saboundji, Michel Andre, et al.
Lung Cancer (Amsterdam, Netherlands)|March 3, 2023
Safety and efficacy of second-line metronomic oral vinorelbine-atezolizumab combination in stage IV non-small-cell lung cancer: An open-label phase II trial (VinMetAtezo)Alain Vergnenegre, Isabelle Monnet, Charles Ricordel, et al.
Plos One|June 27, 2024
Afatinib or Bevacizumab in combination with Osimertinib efficiently control tumor development in orthotopic murine models of non-small lung cancerUlrich Jarry, Megane Bostoen, Jérome Archambeau, et al.
Cancer Medicine|May 16, 2020
Duration of nivolumab for pretreated, advanced non-small-cell lung cancerMargaux Geier, Renaud Descourt, Romain Corre, et al.
Pageof 6

Showing results (21-30 of 54) with videos related to

Sort By:
Pageof 6
Oncotarget|March 2, 2018
Octogenarians with EGFR-mutated non-small cell lung cancer treated by tyrosine-kinase inhibitor: a multicentric real-world study assessing tolerance and efficacy (OCTOMUT study)Romain Corre, Radj Gervais, Florian Guisier, et al.
Oncology|October 3, 2018
Characteristics of Lung Cancer in Patients Younger than 40 Years: A Prospective Multicenter Analysis in FranceLaurence Bigay-Gamé, Suzanna Bota, Laurent Greillier, et al.
Infectious Diseases Now|July 9, 2021
Hypermetabolic pulmonary lesions on FDG-PET/CT: Tularemia or neoplasia?Pauline Martinet, Lydie Khatchatourian, Nadia Saidani, et al.
Lung Cancer (Amsterdam, Netherlands)|January 9, 2020
Immunotherapy rechallenge after nivolumab treatment in advanced non-small cell lung cancer in the real-world setting: A national data base analysisMatteo Giaj Levra, François-Emery Cotté, Romain Corre, et al.
Translational Lung Cancer Research|March 10, 2023
Pembrolizumab plus pemetrexed-carboplatin combination in first-line treatment of advanced non-squamous non-small cell lung cancer: a multicenter real-life study (CAP29)Emmanuelle Renaud, Charles Ricordel, Romain Corre, et al.
Cancer Medicine|August 24, 2022
Real-life second-line epirubicin-paclitaxel regimen as treatment of relapsed small-cell lung cancer: EpiTax studyJosselin Annic, Hélène Babey, Romain Corre, et al.
Targeted Oncology|May 24, 2019
Real-Life Efficacy of Osimertinib in Pretreated Octogenarian Patients with T790M-Mutated Advanced Non-small Cell Lung CancerJean-Bernard Auliac, Karima Saboundji, Michel Andre, et al.
Lung Cancer (Amsterdam, Netherlands)|March 3, 2023
Safety and efficacy of second-line metronomic oral vinorelbine-atezolizumab combination in stage IV non-small-cell lung cancer: An open-label phase II trial (VinMetAtezo)Alain Vergnenegre, Isabelle Monnet, Charles Ricordel, et al.
Plos One|June 27, 2024
Afatinib or Bevacizumab in combination with Osimertinib efficiently control tumor development in orthotopic murine models of non-small lung cancerUlrich Jarry, Megane Bostoen, Jérome Archambeau, et al.
Cancer Medicine|May 16, 2020
Duration of nivolumab for pretreated, advanced non-small-cell lung cancerMargaux Geier, Renaud Descourt, Romain Corre, et al.
Pageof 6